InsiderTrades

Form 4 for MAZE Maze Therapeutics, Inc.

Accepted 2025-02-04 00:00:00 ET · period of report 2025-02-03 · accession 0001415889-25-002957 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2025-02-04 2025-02-03 MAZE Lim Jonathan E Dir C - Cnv Deriv — +308.0K 308.0K New —
DMI 2025-02-04 2025-02-03 MAZE Lim Jonathan E Dir C - Cnv Deriv — -2.60M 0 -100% —
D 2025-02-04 2024-12-09 MAZE Lim Jonathan E Dir D - Sale to Iss — -5,704 0 -100% —
DM 2025-02-04 2024-12-09 MAZE Lim Jonathan E Dir A - Grant $0.00 +14.8K 9,086 New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-03 C A 37,724 — 37,724 I City Hill, LLC — — (F1) Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. (F2) These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.
2 Common Common Stock 2025-02-03 C A 270,232 — 307,956 I City Hill, LLC — — (F3) Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date. (F2) These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.
3 Derivative Series A Preferred Stock 2025-02-03 C D 363,703 — 0 I City Hill, LLC — · — to — 37,724 Common Stock (F1) Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. (F2) These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.
4 Derivative Stock Option (Right to Buy) 2024-12-09 D D 5,704 — 0 D $17.74 · — to 2033-03-08 5,704 Common Stock (F4) This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025. (F6) This option, which was first granted on March 9, 2023, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price. (F5) The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
5 Derivative Stock Option (Right to Buy) 2024-12-09 A A 5,704 — 5,704 D $10.42 · — to 2033-03-08 5,704 Common Stock (F4) This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025. (F6) This option, which was first granted on March 9, 2023, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price. (F5) The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
6 Derivative Series B Preferred Stock 2025-02-03 C D 2,231,381 — 0 I City Hill, LLC — · — to — 270,232 Common Stock (F3) Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date. (F2) These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.
7 Derivative Stock Option (Right to Buy) 2024-12-09 A A 9,086 $0.00 9,086 D $10.42 · — to 2034-12-08 9,086 Common Stock (F4) This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025. (F7) The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.